September 4, 2013 — C. R. Bard Inc. has entered into a definitive merger agreement to acquire Rochester Medical Corp. at a price of $20 per share, or approximately $262 million in the aggregate. The Rochester Medical board of directors unanimously approved the agreement and will recommend that the company's shareholders approve the transaction.
Under the terms of the merger agreement, Rochester Medical shareholders will receive $20 in cash for each share that they hold at the closing of the merger, representing a 37 percent premium over the company's average closing price during the 90 trading days ended Sept. 3, 2013. The acquisition is subject to certain closing conditions specified in the definitive agreement, including regulatory approvals and the approval of Rochester Medical's shareholders. The transaction is expected to close in the fourth calendar quarter of 2013.
Rochester develops, manufactures and markets disposable medical catheters and devices for urological and continence care applications. The company also sells certain ostomy and wound and scar care products and other brands of urological products into the European marketplace.
For more information: www.rocm.com